ICER publishes evidence report on additive cardiovascular disease therapies

12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...

Read more →

ICER releases draft evidence report on diabetes therapies

11 September 2019 - Public comment period now open until 8 October 2019; Requests to make oral comment during public meeting ...

Read more →

Bad diagnosis: health care system muddled, lacking leadership major report finds

3 September 2019 - The review is being led by former prime minister Helen Clark's chief of staff, Heather Simpson. ...

Read more →

Academics and consumer groups protest FDA plan to summarise review documents

29 August 2019 - A Food and Drug Administration proposal to substitute detailed reviews of new drugs written by specific ...

Read more →

Australian Public Assessment Reports for prescription medicines

28 August 2019 - TGA is reviewing the operation of transparency measures and are considering activities to increase transparency of ...

Read more →

Extension to feedback for public consultation - standardised redactions of PBAC Public Summary Documents

19 August 2019 - On 30 July 2019, the Department of Health held an information forum to provide industry, consumers and ...

Read more →

ICER releases draft evidence report on additive cardiovascular disease therapies

24 July 2019 - Public comment period now open until 20 August 2019; requests to make oral comment during public ...

Read more →

PBAC Public Summary Documents (first time rejections and deferrals) - March 2019 meeting

19 July 2019 - The Public Summary Documents (first time rejections and deferrals) from the March 2019 PBAC meeting are ...

Read more →

Drug Utilisation Sub-Committee outcome statement

17 July 2019 - The outcome statement from the June 2019 Drug Utilisation Sub-Committee meeting is now available. ...

Read more →

Drug Utilisation Sub-Committee utilisation analysis public release documents

12 July 2019 - The utilisation analysis public release documents from the February 2019 Drug Utilisation Sub-Committee Meeting are now available. ...

Read more →

PBAC Public Summary Documents - March 2019 meeting

5 July 2019 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2019 PBAC ...

Read more →

Prices of Canadian generic medicines below international average

29 May 2019 - PMRPB: Canadian price declines steepest of all OECD countries. ...

Read more →

Asthma Stakeholder Meeting December 2018 – outcome statement

22 May 2019 - The outcome statement for the severe asthma stakeholder meeting held on 14 December 2018 is now available. ...

Read more →

PD-L(1) checkpoint inhibitor stakeholder meeting outcome statement

12 April 2019 - The outcome statement for the PD-(L)1 checkpoint inhibitor stakeholder meeting held on 8 February 2019 , ...

Read more →

Institute for Clinical and Economic Review posts draft scoping document for the assessment of treatments for rheumatoid arthritis

11 April 2019 - Document open to public comment until 1 May 2019. ...

Read more →